35,073 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Cantor Fitzgerald L. P.

Cantor Fitzgerald L. P. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 35,073 shares of the company's stock, valued at approximately $3,017,000.

Other institutional investors have also modified their holdings of the company. Center for Financial Planning Inc. raised its holdings in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL raised its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after acquiring an additional 300 shares during the period. Transce3nd LLC bought a new position in Novo Nordisk A/S in the fourth quarter worth about $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $39,000. Finally, Albion Financial Group UT grew its holdings in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after purchasing an additional 278 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $2.80 on Tuesday, reaching $66.32. 10,488,030 shares of the stock traded hands, compared to its average volume of 6,255,250. The firm's fifty day simple moving average is $70.60 and its 200 day simple moving average is $87.08. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a market cap of $297.63 billion, a price-to-earnings ratio of 20.16, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date was Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's payout ratio is presently 49.54%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. Finally, BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.